An international consortium of for-profit and non-profit entities advancing frontier science and technology development, acquisition and deployment, from R&D and technoindustrial ecosystem intelligence to productization, platformization, financial commoditization, technophilanthropy, policy and practical deployment.
Deep Knowledge Group develops, acquires and deploys frontier technology and knowledge assets through a connected consortium of commercial and non-profit entities.
Our core return on impact is accelerated, de-risked deployment that improves human health, intelligence and opportunity. Healthy life expectancy (HALE) and quality-adjusted life years (QALYs) are central measures of the social outcomes we prioritise.
Commercial development and technophilanthropy work together: building durable practical capability while broadening access to the benefits of frontier science and technology.
Commercial entities and non-profit programmes advance a shared purpose: accelerating and de-risking the deployment of frontier science and technology to improve human health, intelligence and opportunity. Commercial value and technophilanthropy provide complementary routes to that purpose.
Our work has progressed from analytical, classification and benchmarking frameworks to end-to-end ecosystem mapping, extensive databases, forecasting methodologies and proprietary technology stacks. These foundations support the development and acquisition of technology, intellectual property and knowledge assets.
The entities and projects presented here are one layer of a wider programme. Proprietary analytics, R&D and technology development operate alongside publicly disclosed work, combining capabilities ready for deployment now with long-horizon scientific and technological research directed at the next decade.
Explore DKG projects and divisions across intelligence, longevity, frontier technology, finance, deployment and social good.
International indexes, scientific and industrial profiling, regional intelligence and connected analytical platforms.
Explore intelligence projects →From longevity medicine and clinical blueprints to digital operating systems, habitats, modular longevity and finance.
Explore longevity projects →Technology and knowledge asset development, advanced matching and the analytical foundations of early entry.
Explore frontier technology →More than a decade of analytical development connects classification, benchmarking and forecasting frameworks with end-to-end ecosystem mapping, large structured databases and proprietary intelligence stacks. This continuous system supports knowledge-asset development and acquisition, selective capital deployment and decisions grounded in technological reality.
Develop the taxonomies, analytical methods and readiness criteria that make a frontier domain comparable and intelligible.
Industry frameworks ↗Build extensive structured databases linking technologies, organisations, investors, institutions, infrastructure and expertise.
Ecosystem mapping ↗Translate those databases into big-data analytics, investment intelligence and dashboards for internal use and commercial applications.
Analytics and dashboards ↗Use that knowledge to select technology and IP, build projects and spinouts, and bring practical capabilities into real-world use.
Projects and priority domains ↗Long-standing work making complex industrial ecosystems visible and understandable.
Connected visual analytics support a deeper view of technology development and opportunity.
A comprehensive longevity ecosystem: advanced medicine and functional medicine, digital infrastructure, clinics, habitats, modular longevity, real estate and finance.
Milestones in Longevity.Group’s own account of its development, built on DKG’s long-standing industry work.
Longevity Medicine, Functional Medicine 2.0, protocols, clinical pathways and clinics.
Core longevity infrastructure, LBams, Longevity Club and integrated knowledge assets.
Habitats, modular infrastructure, longevity real estate and implementation blueprints.
Industry databases, profiling, investment technologies and longevity as a new asset class.
Deep Knowledge Ventures made its inaugural longevity-industry investment in 2014, combining artificial intelligence and biotechnology.
Frameworks, ecosystem maps, books and detailed analysis connecting science, technology, medicine and finance.
DKG’s published record described 50,000 companies, 12,000 investors and 1,200 R&D hubs across 20 sectors.
Insilico Medicine completed the largest Hong Kong biotech IPO of 2025 by fundraising size.
Historical record: DKV’s 2014 seed-investment account; DKG’s 2022 Davos presentation and database description; Insilico Medicine’s 30 December 2025 IPO announcement. Database figures are dated, not current totals.
DeepTech and longevity require financial infrastructure that can recognise scientific capability, technology, intellectual property and long-term societal value.
DKG’s agenda connects deep ecosystem analytics with investment technologies, valuation frameworks and emerging financial structures—helping longevity develop as a new asset class and health become a new form of wealth.
An infrastructure development agenda for the emerging DeepTech and longevity economy.
Explore 25 priority domains within a broader operating system of public projects, proprietary intelligence, R&D and technology development.
Explore books connecting longevity science, medicine, technology and the industries shaping longer, healthier lives.
The Group’s long-standing work combines detailed ecosystem profiling with published knowledge that helps researchers, institutions and readers understand a complex and evolving field.
Public references, commentary and collaboration across government, law and industry. Each acknowledgement is shown with the work and context it concerns.
.jpg)
His office acknowledged Israel’s leading position in DKG’s COVID-19 health safety assessment.
Publicly referenced the Group’s COVID-19 Safety Ranking in August 2020.
Commented on Germany’s leading European position in the pandemic assessment.
Referenced DKG’s research and Hungary’s fourth-place European ranking.
Referenced Switzerland’s first-place standing in the assessment of pandemic resilience.
.jpg)
“For health ministers trying to decide when and how to deploy AI in systems and across systems, this AI competitiveness report will be invaluable…”
.png)
“This report sheds light on that reality by showing that competitiveness comes from the ability to connect research excellence with industrial execution, clinical validation, regulatory reliability and capital formation.”
.png)
“This report rightly treats accountability, explainability and legal certainty as the foundations of competitiveness rather than as obstacles to it.”
“Hong Kong came third in the Global AI Competitiveness Index, after only New York and London…”
“I am very pleased to collaborate with Deep Knowledge Analytics to launch the UAE’s first Life Sciences report, which covers the full Life Sciences and Longevity landscape across the country.”
A connected digest of DKG research, public commentary, broadcast appearances and official announcements.
Two compact video embeds, with captions identifying the index and original context.
Opening speech · Global AI Competitiveness Index Part 5
Comments on Global AI Competitiveness Index Part 6
Deep Knowledge Group Dubai · COVID City Ranking
Kate Batz · FemTech Analytics
Baha Hamadi · DKG Dubai Office
Selected appearances across longevity, healthcare, technology and the economy.
Dmitry Kaminskiy’s keynote at the 2022 longevity summit, held during the World Economic Forum annual meeting.
Explore this appearance ↗
A long-standing contribution to the conversation on longevity, demographic change and economic development.
Explore this appearance ↗
Dmitry Kaminskiy speaking on healthcare and longevity at the 2024 summit.
Explore this appearance ↗For institutions, investors, researchers, operators and partners advancing frontier technology and societal benefit.
Our primary return: healthier lives and wider opportunity.
DeepTech for Social Good is the Group’s core return on impact. Commercial and non-profit programmes pursue complementary routes to accelerated, de-risked and democratised deployment of frontier science and technology.
Build durable practical capability
Develop and acquire technology and knowledge assets, support viable ventures, and connect research with capital and implementation.
Explore the commercial portfolio →Advance technology for public benefit
Apply research, open knowledge, analytics and techno-philanthropy to health, inclusion and significant societal challenges.
Explore techno-philanthropy ↗